Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

DNA issues

P Meulien1

  • 1Department of Research, Pasteur Mérieux Connaught, Marcy l'Etoile, France.

Developments in Biological Standardization
|September 16, 1998
PubMed
Summary
This summary is machine-generated.

Cellular DNA in biological products poses minimal risk of causing tumors in patients. Current understanding of DNA nature and fate after administration confirms its safety profile.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Retrospective cephalometric analysis for surgically treated obstructive sleep apnea: therapeutic deductions].

Annales d'oto-laryngologie et de chirurgie cervico faciale : bulletin de la Societe d'oto-laryngologie des hopitaux de Paris·2001
Same author

Identification of a human epitope in hepatitis C virus (HCV) core protein using a molecularly cloned antibody repertoire from a non-symptomatic, anti-HCV-positive patient.

The Journal of general virology·2000
Same author

Intradermal DNA immunization by using jet-injectors in mice and monkeys.

Vaccine·1999
Same author

Paving the way towards DNA vaccines.

Nature medicine·1995
Same author

Induction of virus-specific cytotoxic T lymphocytes in vivo by liposome-entrapped mRNA.

European journal of immunology·1993
Same author

Processing and characterization of recombinant von Willebrand factor expressed in different cell types using a vaccinia virus vector.

Thrombosis and haemostasis·1992
Same journal

International challenges and public policy issues.

Developments in biological standardization·2000
Same journal

Regulation of biologicals in China.

Developments in biological standardization·2000
Same journal

ICH activities on biotech topics.

Developments in biological standardization·2000
Same journal

Regulation of biologicals in the European Union.

Developments in biological standardization·2000
Same journal

Standardisation and licensing of combination vaccines based on DTP.

Developments in biological standardization·2000
Same journal

Control of foot-and-mouth disease by vaccination.

Developments in biological standardization·2000
See all related articles

Area of Science:

  • Biotechnology
  • Genotoxicology
  • Patient Safety

Background:

  • The long-standing debate on cellular DNA contamination in biological products centers on potential oncogenesis.
  • Concerns exist regarding the risk of tumor formation in recipients of biological products containing cellular DNA.

Purpose of the Study:

  • To evaluate the oncogenic potential of cellular DNA in biological products.
  • To assess the risk posed by cellular DNA contamination in patients receiving biological therapies.

Main Methods:

  • Review of current scientific knowledge on the nature of cellular DNA.
  • Analysis of the fate and behavior of administered cellular DNA in vivo.
  • Risk assessment based on existing data regarding DNA degradation and clearance.

Related Experiment Videos

Main Results:

  • Cellular DNA in biological products is unlikely to cause tumors.
  • The in vivo fate of administered DNA indicates limited oncogenic potential.
  • Current data suggests a minimal risk to patients from DNA contamination.

Conclusions:

  • The risk of tumor formation from cellular DNA in biological products is minimal.
  • Understanding the fate of DNA post-administration supports a favorable safety profile.
  • Patients receiving biological products with cellular DNA contamination are at low risk.